Retour
Prix MetaStat Inc (MTST)
Graphique du cours de l'action MTST
MTST Gagner
MetaStat Inc
$0
0%
$0
À la fermeture : Jan 16, 16:00:00 GMT-5
$0
0%
$0
Post-Marché: Jan 16, 20:00:00 GMT-5
Pas encore de donnéesEarnings FAQ
Comment le bénéfice par action récent de MTST se compare-t-il aux attentes ?
Comment les revenus de MetaStat Inc MTST se sont-ils comportés au dernier trimestre ?
Quelle est l'estimation des revenus pour MetaStat Inc ?
Quel est le score de qualité des bénéfices pour MetaStat Inc ?
Quand MetaStat Inc publie-t-elle ses résultats ?
Quels sont les bénéfices attendus de MetaStat Inc ?
MetaStat Inc a-t-elle dépassé les attentes en matière de bénéfices ?
Statistiques clés
Clôture préc.
$0.0006
Prix d'ouverture
$0.0001
Plage de la journée
$0.0001 - $0.0006
Plage de 52 semaines
$0.0001 - $0.0007
Volume
16.9K
Volume moyen
194
BPA (TTM)
-0.57
Rendement en dividend
--
Capitalisation boursière
$3.5K
Qu’est-ce que MTST ?
MetaStat, Inc. engages in the research, development, and commercialization of pharmaceutical products. The company is headquartered in Boston, Massachusetts. The company went IPO on 2008-02-13. The firm's therapeutic focus targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer. The firm's product development programs are focused on developing drug candidates and companion diagnostic tests that target the MENA pathway. Its pipelines include MENA Diagnostic Assay and MetaSite Breast Assay. The MENA diagnostic assay is a tissue-based quantitative immunofluorescence (QIF) test that measures expression of the pro-metastatic MENA protein splice-variant which is associated with poor outcomes and metastasis in early-stage breast cancer (ESBC) and squamous cell carcinoma of the Lung. MetaSite Breast is an immunohistochemistry test (IHC) that measures micro-anatomical intravasation sites (TMEM) at blood vessels within the tumor microenvironment which are clinically validated as prognostic markers of metastasis in hormone receptor-positive (HR+) ESBC.
Fonctionnalités
Stratégies de trading
Ressources
© 2025 Finture Development Limited. All rights reserved